6931-84-6

Usage

Uses

Used in Pharmaceutical Industry:
1-palmitoyl-2-linoleoylphosphatidylcholine is used as a key component in the formulation of liposomes for drug delivery. Its amphiphilic nature allows it to form stable bilayer structures, which can encapsulate and protect hydrophobic and hydrophilic drugs, enhancing their solubility, bioavailability, and targeted delivery.
Used in Cosmetic Industry:
1-palmitoyl-2-linoleoylphosphatidylcholine is used as an emulsifier and skin conditioning agent in cosmetic products. Its ability to form lipid bilayers helps to stabilize emulsions and improve the texture and feel of creams, lotions, and other skincare formulations. Additionally, it may contribute to maintaining the skin's barrier function and moisture levels.
Used in Food Industry:
1-palmitoyl-2-linoleoylphosphatidylcholine is used as an emulsifier and stabilizer in various food products. It helps to improve the texture, consistency, and shelf life of foods by reducing the tendency of ingredients to separate. It is particularly useful in the production of margarine, spreads, and other fat-based products.
Used in Biomedical Research:
1-palmitoyl-2-linoleoylphosphatidylcholine is used as a model lipid for studying the properties and functions of biological membranes. Its well-defined structure allows researchers to investigate the behavior of lipids in model systems, providing insights into the organization, dynamics, and interactions of membrane components.

InChI:InChI=1/C42H80NO8P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h14,16,20-21,40H,6-13,15,17-19,22-39H2,1-5H3/b16-14-,21-20-

Upstream product

• 60-33-3 linoleic acid 
• 17364-16-8 1-palmitoyl-sn-glycero-3-phosphocholine 
• 1487-50-9 1-O-hexadecanoyl-3-O-benzyl-sn-glycerol 
• 57-10-3 1-hexadecylcarboxylic acid 
• 506-32-1 all cis 5,8,11,14-eicosatetraenoic acid 
• 1455-05-6 2-chloroethyl phosphorodichloridate 
• 65886-78-4 1-O-palmitoyl-2-arachidonoyl-glycerol 
• 75-50-3 trimethylamine 
• 14912-92-6 caesium palmitate 
• 34688-34-1 glycerolcholine phosphate 
• 55357-38-5 choline tosylate 
• 17364-18-0 1-palmitoyllysophosphatidylcholine 
• 256494-15-2 1-O-palmitoyl-2-arachidonoyl-3-benzylglycerol 
• 256494-17-4 1-O-palmitoyl-3-[methyl α-(2,4-dinitrophenyl)acetate]glycerol 

Downstream Products

• 54672-38-7 (R)-1,2-diacetoxy glycerylphosphoryl choline 
• 117205-52-4 1-hexadecanoyl-2-(9-carboxynonanoyl)glycerophosphocholine 
• 17364-16-8 1-palmitoyl-sn-glycero-3-phosphocholine 
• 10219-69-9 (R,S)-coriolic acid 
• 73543-67-6 (10E,12Z)-9-hydroxy-10,12-octadecadienoic acid 
• 115185-06-3 9-Hode 
• 32819-31-1 [14C]-13-Hydroxyoctadecadienoic acid 

Relevant academic research and scientific papers

Synthesis of phosphatidylcholine with conjugated linoleic acid and studies on its cytotoxic activity

Phospholipids with conjugated linoleic acid (CLA), which are potential lipid prodrugs, were synthesised. CLA was obtained by the alkali-isomerisation of linoleic acid and was subsequently used in the synthesis of 1,2-di(conjugated)linoleoyl-sn-glycero-3-phosphocholine in good (82%) yield. 1-Palmitoyl-2-(conjugated)linoleoyl-sn-glycero-3-phosphocholine was obtained by a two-step synthesis in 87% yield. All the compounds were tested in an in vitro cytotoxicity assay against two human cancer cell lines, HL-60 and MCF-7, and a mouse fibroblast cell line, Balb/3T3. The free form of CLA exhibited the highest activity against all cancer cell lines. Results obtained for the Balb/3T3 line proved that phosphatidylcholine derivatives decreased the cytotoxic effect of CLA against healthy cell lines.

NOVEL FORMULATION OF DEHYDRATED LIPID VESICLES FOR CONTROLLED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT VIA INHALATION

A new formulation of dehydrated lipid vesicles employs a vesicle preserver and permits the control of release and delivery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical formulation provides controlled release of the active pharmaceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, reduced systemic side effects, reduced toxicity.

Total synthesis of 2-(5,6-epoxyisoprostane A2)phosphorylcholine and elucidation of the relative configuration of the isoprostane moiety

(Chemical Equation Presented) The two possible diastereomers of 5,6-epoxyisoprostane A2 were synthesized efficiently through aldol condensations of a substituted cyclopentenone and the corresponding epoxyaldehydes (see picture). The relative configurations of the products were assigned by comparing their 1H NMR spectra with literature data. Condensation of the epoxyisoprostane A2 with lysophosphorylcholine (lyso-PC) then furnished the title lipid.

A rapid condensation between lysophosphorylcholine and fatty acids with an easily separable amine base

With 2,6-Cl2C6H3COCl and 1-methylimidazole, the title condensation completed at room temperature within 12 hours, which is shorter time than that with the standard DCC/DMAP system. Use of easily separable 1-methylimidazole from the crude product by chromatography is an additional advantage of the present reagent system. Georg Thieme Verlag Stuttgart.

Novel pharmaceutical composition of ceftiofur

The present invention relates to a pharmaceutical oily suspension comprising cephalosporin antibiotic or its pharmaceutically acceptable salt, at least a biocompatible oil, a wetting agent, a dispersing agent and a resuspendibility enhancer, said suspension has improved properties, such as resuspendibility and chemical stability and process thereof.

Deuterated cyclosporine analogs and their use as immunomodulating agents

Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives.

2-methyl-thieno-benzodiazepine formulation

The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

Synthesis of a small library of mixed-acid phospholipids from D-mannitol as a homochiral starting material

Synthesis of a series of mixed-acid phospholipids containing a polyunsaturated fatty acid using a newly protecting strategy are described. Thus, benzyl and methyl α-(2,4-dinitrophenyl)acetic acid which were respectively removed by BCl3 and 354 nm light are used as protecting groups.

Process for the preparation of L-α-glycerylphosphoryl-choline and of L-α-glycerylphosphorylethanolamine

A process for the purification of glycerylphosphorylcholine (GPC) and glycerylphosphorylethanolamine (GPE) from crude mixtures by eluting the latter on a cationic resin in acid form equilibrated in an anhydrous solvent, washing the resin with alcohol or a hydrated mixture thereof followed by washing with water, and then eluting on a strong basic resin in OH form to separate purified GPC and GPE.

Modified biologically active proteins

A modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linking group and a pharmaceutical composition comprising the modified biologically active protein in a pharmaceutically-acceptable carrier. The biologically active proteins include antibodies, superoxide dismutase, insulin, and callidinogenase. Lecithin derivatives are also disclosed.